Biomarin Retained Earnings from 2010 to 2025

BMRN Stock

USD 64.34 0.15 0.23%

Biomarin Pharmaceutical Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to drop to about -587.4 M. Retained Earnings is the cumulative amount of net income that Biomarin Pharmaceutical retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

1999-03-31

Previous Quarter

-425.7 M

Current Value

-319.6 M

Quarterly Volatility

489.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 126 M, Interest Expense of 18 M or Selling General Administrative of 542 M, as well as many indicators such as Price To Sales Ratio of 8.18, Dividend Yield of 0.0 or PTB Ratio of 3.99. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Biomarin Pharmaceutical over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Biomarin Pharmaceutical's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (621.55 M)

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Retained Earnings

Timeline

Biomarin Retained Earnings Regression Statistics

	Arithmetic Mean	(905,281,508)
	Geometric Mean	678,294,253
	Coefficient Of Variation	(55.07)
	Mean Deviation	386,058,244
	Median	(789,199,000)
	Standard Deviation	498,549,045
	Sample Variance	248551.2T
	Range	1.7B
	R-Value	(0.17)
	Mean Square Error	258381.5T
	R-Squared	0.03
	Significance	0.52
	Slope	(18,062,460)
	Total Sum of Squares	3728267.3T

Biomarin Retained Earnings History

	2025	-587.4 M
	2024	-559.4 M
	2023	-621.6 M
	2022	-789.2 M
	2021	-925.7 M
	2020	-861.6 M
	2019	-1.7 B

Other Fundumenentals of Biomarin Pharmaceutical

Retained Earnings Total Equity

Biomarin Pharmaceutical Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	0.56	-0.2	0.57	0.96	0.97	0.98	0.41	0.5	0.26	0.74	0.61	0.98	0.41	0.74	0.98	0.82	0.87	0.72	-0.47	0.79	0.69	0.72
Total Stockholder Equity	1.0		0.53	-0.14	0.53	0.97	0.95	0.97	0.36	0.46	0.23	0.71	0.58	0.97	0.39	0.72	0.99	0.81	0.85	0.72	-0.46	0.82	0.72	0.75
Net Debt	0.56	0.53		-0.45	0.42	0.45	0.61	0.48	0.63	0.77	-0.25	0.61	0.52	0.61	0.06	0.77	0.49	0.49	0.7	0.56	-0.43	0.34	0.27	0.21
Retained Earnings	-0.2	-0.14	-0.45		-0.77	-0.03	-0.37	-0.19	-0.77	-0.63	-0.11	-0.56	-0.44	-0.38	-0.43	-0.58	-0.05	-0.11	-0.49	-0.27	0.63	0.33	0.34	0.29
Accounts Payable	0.57	0.53	0.42	-0.77		0.49	0.67	0.56	0.73	0.47	0.44	0.63	0.29	0.69	0.53	0.72	0.44	0.28	0.67	0.56	-0.62	0.09	-0.09	0.24
Net Receivables	0.96	0.97	0.45	-0.03	0.49		0.89	0.96	0.2	0.35	0.29	0.61	0.41	0.91	0.29	0.6	0.96	0.73	0.76	0.64	-0.39	0.84	0.69	0.82
Total Liab	0.97	0.95	0.61	-0.37	0.67	0.89		0.96	0.52	0.6	0.34	0.8	0.67	0.98	0.47	0.78	0.91	0.79	0.88	0.71	-0.5	0.67	0.57	0.63
Total Current Assets	0.98	0.97	0.48	-0.19	0.56	0.96	0.96		0.3	0.52	0.32	0.72	0.58	0.95	0.41	0.66	0.96	0.81	0.83	0.64	-0.44	0.78	0.68	0.74
Intangible Assets	0.41	0.36	0.63	-0.77	0.73	0.2	0.52	0.3		0.58	0.12	0.65	0.54	0.52	0.42	0.82	0.25	0.34	0.63	0.55	-0.52	-0.03	-0.03	-0.06
Short Term Investments	0.5	0.46	0.77	-0.63	0.47	0.35	0.6	0.52	0.58		-0.15	0.62	0.66	0.57	0.25	0.68	0.42	0.53	0.67	0.36	-0.53	0.18	0.31	0.07
Short Term Debt	0.26	0.23	-0.25	-0.11	0.44	0.29	0.34	0.32	0.12	-0.15		0.25	-0.02	0.24	0.45	0.05	0.17	0.14	0.1	0.24	0.11	0.1	-0.07	0.33
Common Stock	0.74	0.71	0.61	-0.56	0.63	0.61	0.8	0.72	0.65	0.62	0.25		0.77	0.79	0.36	0.81	0.64	0.76	0.87	0.7	-0.43	0.51	0.4	0.38
Long Term Debt	0.61	0.58	0.52	-0.44	0.29	0.41	0.67	0.58	0.54	0.66	-0.02	0.77		0.64	0.41	0.65	0.56	0.78	0.72	0.37	-0.27	0.37	0.54	0.11
Property Plant Equipment	0.98	0.97	0.61	-0.38	0.69	0.91	0.98	0.95	0.52	0.57	0.24	0.79	0.64		0.46	0.82	0.93	0.78	0.91	0.71	-0.56	0.68	0.58	0.63
Current Deferred Revenue	0.41	0.39	0.06	-0.43	0.53	0.29	0.47	0.41	0.42	0.25	0.45	0.36	0.41	0.46		0.52	0.38	0.49	0.54	0.48	-0.38	0.14	0.1	0.13
Good Will	0.74	0.72	0.77	-0.58	0.72	0.6	0.78	0.66	0.82	0.68	0.05	0.81	0.65	0.82	0.52		0.67	0.72	0.94	0.8	-0.58	0.47	0.38	0.33
Net Tangible Assets	0.98	0.99	0.49	-0.05	0.44	0.96	0.91	0.96	0.25	0.42	0.17	0.64	0.56	0.93	0.38	0.67		0.82	0.82	0.67	-0.41	0.86	0.77	0.76
Long Term Debt Total	0.82	0.81	0.49	-0.11	0.28	0.73	0.79	0.81	0.34	0.53	0.14	0.76	0.78	0.78	0.49	0.72	0.82		0.85	0.67	-0.25	0.81	0.8	0.57
Capital Surpluse	0.87	0.85	0.7	-0.49	0.67	0.76	0.88	0.83	0.63	0.67	0.1	0.87	0.72	0.91	0.54	0.94	0.82	0.85		0.79	-0.56	0.64	0.53	0.48
Long Term Investments	0.72	0.72	0.56	-0.27	0.56	0.64	0.71	0.64	0.55	0.36	0.24	0.7	0.37	0.71	0.48	0.8	0.67	0.67	0.79		-0.54	0.63	0.37	0.57
Short Long Term Debt	-0.47	-0.46	-0.43	0.63	-0.62	-0.39	-0.5	-0.44	-0.52	-0.53	0.11	-0.43	-0.27	-0.56	-0.38	-0.58	-0.41	-0.25	-0.56	-0.54		-0.09	-0.05	-0.18
Net Invested Capital	0.79	0.82	0.34	0.33	0.09	0.84	0.67	0.78	-0.03	0.18	0.1	0.51	0.37	0.68	0.14	0.47	0.86	0.81	0.64	0.63	-0.09		0.86	0.85
Net Working Capital	0.69	0.72	0.27	0.34	-0.09	0.69	0.57	0.68	-0.03	0.31	-0.07	0.4	0.54	0.58	0.1	0.38	0.77	0.8	0.53	0.37	-0.05	0.86		0.66
Capital Stock	0.72	0.75	0.21	0.29	0.24	0.82	0.63	0.74	-0.06	0.07	0.33	0.38	0.11	0.63	0.13	0.33	0.76	0.57	0.48	0.57	-0.18	0.85	0.66

Click cells to compare fundamentals

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as Retained Earnings, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-559.4 M	-587.4 M
Retained Earnings Total Equity	-833.1 M	-874.8 M

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.607

Earnings Share

1.66

Revenue Per Share

14.529

Quarterly Revenue Growth

0.283

Return On Assets

0.03

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Retained Earnings from 2010 to 2025

Latest Biomarin Pharmaceutical's Retained Earnings Growth Pattern

Biomarin Retained Earnings Regression Statistics

Biomarin Retained Earnings History

Other Fundumenentals of Biomarin Pharmaceutical

Biomarin Pharmaceutical Retained Earnings component correlations

About Biomarin Pharmaceutical Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY